FBXO43: A Potential Drug Target and Biomarker (G286151)

Target Name: FBXO43

NCBI ID: G286151

FBXO43

FBXO43: A Potential Drug Target and Biomarker

FBXO43, also known as ERP1, is a protein that is expressed in various tissues and cells in the body. It is a member of the endoplasmic reticulum (ER) protein family, which includes proteins that play a critical role in the delivery and processing of proteins from the ER to the cytosol.

One of the unique features of FBXO43 is its ability to interact with various drug molecules, making it an attractive target for researchers looking for new pharmaceuticals. Its high affinity for drug molecules has been identified as a potential mechanism for its use as a drug or biomarker.

FBXO43 has been shown to interact with a wide range of drug molecules, including small molecules, peptides, and proteins. Its interactions with drugs have been shown to be dose-dependent and can be modulated by various factors, such as the presence of bound drugs and the concentration of FBXO43.

One of the most promising applications of FBXO43 as a drug target is its potential to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to interact with a wide range of drug molecules makes it a versatile candidate for drug development.

FBXO43 has been shown to interact with a variety of small molecules, including drugs that are currently being used to treat various diseases. For example, studies have shown that FBXO43 interacts with the drug rapamycin, which is used to treat cancer and other diseases. Rapamycin is an inhibitor of the mTOR pathway, which is involved in cell growth and division.

FBXO43 has also been shown to interact with other drugs that are used to treat various diseases, including neurodegenerative disorders and autoimmune disorders. For example, studies have shown that FBXO43 interacts with the drug pimozide, which is used to treat Parkinson's disease. Pimozide is an inhibitor of the dopamine receptor, which is involved in the treatment of Parkinson's disease.

FBXO43 has also been shown to interact with proteins that are involved in the development and progression of various diseases. For example, studies have shown that FBXO43 interacts with the protein PDGF-BB, which is involved in the development and progression of cancer.

In addition to its potential use as a drug target, FBXO43 has also been shown to have potential as a biomarker. Its high affinity for drug molecules makes it an attractive candidate for use as a biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune disorders.

FBXO43 has been shown to interact with a variety of proteins that are involved in the development and progression of these diseases. For example, studies have shown that FBXO43 interacts with the protein PDGF-BB, which is involved in the development and progression of cancer.

FBXO43 has also been shown to interact with the protein NF-kappa-B, which is involved in the development and progression of neurodegenerative disorders. Its interactions with these proteins make it a potential candidate for use as a biomarker for these diseases.

In conclusion, FBXO43 is a protein that has shown potential as a drug target and biomarker. Its high affinity for drug molecules and its ability to interact with a variety of proteins involved in the development and progression of various diseases make it an attractive candidate for further research and development. Further studies are needed to fully understand its potential as a drug or biomarker.

Protein Name: F-box Protein 43

Functions: Required to establish and maintain the arrest of oocytes at the second meiotic metaphase until fertilization. Acts by inhibiting the anaphase-promoting complex/cyclosome (APC/C) ubiquitin ligase. Probably recognizes and binds to some phosphorylated proteins and promotes their ubiquitination and degradation (PubMed:34052850, PubMed:34595750). Plays a vital role in modulating the ubiquitilation of CCNB1 and CDK1 during gametogenesis

The "FBXO43 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO43 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets